LCTX vs TMUS · rev $2.8M vs P/E 19, rev $22.79B
Lineage Cell Therapeutics Inc (LCTX) versus T-Mobile US Inc (TMUS) — a side-by-side from cached financials, not a winner call.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
T-Mobile US Inc (TMUS) is a telecom services company listed on NASDAQ. It is led by Mike Sievert.
Latest reported LCTX revenue for 2026-06-30 was $2.8M. Net income was -$3.3M. Revenue was up 62.0% from 2026-03-31 to 2026-06-30. LCTX currently screens at market cap $213.6M.
Latest reported TMUS revenue for 2026-06-30 was $22.79B. Net income was $3.24B. Revenue was down 1.4% from 2026-03-31 to 2026-06-30. TMUS currently screens at market cap $196.21B and trailing P/E 19.3.
LCTX currently screens at market cap $213.6M. TMUS currently screens at market cap $196.21B and trailing P/E 19.3.
Not investment advice. Open the LCTX and TMUS stock pages for the full models.
Not investment advice.